You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Madras HC notice to Centre on plea to declare Covishield vaccine as unsafe

The petitioner, 41-year old Asif Riaz, also sought an interim injunction restraining the Central government and the Drugs Controller General of India from continuing with administering Covishield

Topics
Madras High Court | Coronavirus Vaccine | Bharat Biotech

Press Trust of India  |  Chennai 

Covishield

The on Friday

issued notice to the Centre and others, including of India, on a plea from a man who alleged serious side effects after being administered the Covishield vaccine last year during trial.

In his plea, which came up before Justice Abdul Quddhose, the petitioner sought a declaration that the traumatic health issues he faced following vaccination was a 'serious adverse event' as defined in the New Drugs and Clinical Trial Rules (NDCTR), 2019.

The Covishield vaccine should hence be declared 'not safe' he pleaded and also sought a direction to the SII to provide him a compensation of Rs five crore.

The petitioner, 41-year old Asif Riaz, also sought an interim injunction restraining the Central government and the Drugs Controller General of India from continuing with administering Covishield vaccine, pending disposal of his petition.

According to him, he volunteered in the phase-III trial of the vaccine and he was inoculated on October 1 last year at Sri Ramachandra Institute of Higher Education and Research here.

He experienced severe trauma due to acute neuro encephalopathy, a severe neurological disorder from October 11 to 26 and this was a serious adverse event as defined in NDCTR.

To his legal notice seeking compensation,SII replied last December that his condition was not related to the trial vaccine and the firm offered no proof to support such a view, he said.

The Director General of the Indian Council of Medical Research, in reply to his legal notice, merely stated that any serious event is compensated as per the NDCTR.

Despite request, he received no reply from the Drugs Controller of India on the report of an independent committee it appointed, which said the adverse event he went through had no link to the vaccine.

This panel neither heard him nor physically examined him before submitting its report, he said and sought constitution of an expert committee to go into records and give its view.

The petitioner said he has "...no end in sight for complete recovery," from the side effects following the vaccination.

The court ordered notice to the Union Health Secretary, DCGI, Director General of ICMR, and CEO of SII and chief of the Sri Ramachandra's ethics panel.

The matter has been posted for March 26.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, February 19 2021. 21:30 IST
RECOMMENDED FOR YOU